1025P Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers von Pakola, S.A., Jalkanen, K., Alanko, T.V., Clubb, J.H.A., Quixabeira, D.C.A., Jirovec, E., Kudling, T., Arias, V., Korpisaari, R., Jaakkola, M., Kononen, J.T., Sormunen, J., Pellinen, T., Haybout, L., Kistler, C., Sorsa, S., Havunen, R., Santos, J.M., Cervera-Carrascon, V., Hemminki, A.

Volltext

231P Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOT... von Goh, J.C.H., Piulats, J.M., Gross-Goupil, M., Vaishampayan, U.N., de Wit, R., Alanko, T.V., Fukasawa, S., Tabata, K., Feyerabend, S., Berger, R., Wu, H., Kim, J., Schloss, C., de Bono, J.S., Antonarakis, E.S.

Volltext

611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-... von Antonarakis, E.S., Piulats, J.M., Gross-Goupil, M., Goh, J.C., Vaishampayan, U.N., De Wit, R., Alanko, T.V., Fukasawa, S., Tabata, K., Feyerabend, S., Berger, R., Ojamaa, K., Hoimes, C.J., Sezer, A., Omlin, A.G., Yachnin, J., Niu, C., Poehlein, C.H., Schloss, C., de Bono, J.S.

Volltext